Breast Cancer
Conditions
Brief summary
To determine the accuracy of AMH postchemotherapy in predicting permanent menopause after chemotherapy in breast cancer patients who did not use OFS before menopause
Detailed description
For early breast cancer women who are premenopausal, after receiving chemotherapy (neoadjuvant chemotherapy or adjuvant chemotherapy), not using OFS as ovarian suppression, AMH, E2 and FSH levels will be measured by blood sampling before chemotherapy, at the end of chemotherapy and 1 month, 3 months, 6 months, 12 months, 18 months and 24 months after chemotherapy. The menstrual status of patients will be also followed up. At several timing, investigators will analyze AMH level, E2 level, FSH level, proportion of unmeasured AMH (AMH≤0.02ng/ml), proportion of E2 that conforms to menopausal status (E2≤30ng/L), proportion of FSH that conforms to menopausal status (FSH \> 30U/L), proportion of persistent amenia (no menstruation from the end of chemotherapy to the evaluation time) and incidence of adverse reactions
Interventions
None listed
Sponsors
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
40 Years to 59 Years
Healthy volunteers
No
Inclusion criteria
1. Age over 40(include 40 years old), or before 60, female 2. Primary invasive breast cancer diagnosed by histopathology, except of occult breast cancer, inflammatory breast cancer and Paget's disease 3. Operable patients with no distant metastases at diagnosis (stage T1-T3, any N, M0) 4. The patient was at premenopausal status when first diagnosed (had menstruation in the last 12 months or hormone levels not reached menopause when diagnosed, E2 \> 30ng/L, FSH≤30U/L) 5. The patient has used chemotherapy (neoadjuvant chemotherapy or adjuvant chemotherapy) after diagnosis
Exclusion criteria
1. Age before 40, or over 60(include 60 years old) 2. Patient who accepted bilateral ovariectomy or ovarian radiotherapy 3. Patient who used gonadotropin-releasing hormone agonist ( GnRHa) 4. Stage IV (metastatic) breast cancer 5. The patient was at postmenopausal status when first diagnosed (no menstruation in the past 12 months or hormone levels reached menopause when diagnosed, E2≤30ng/L, FSH \> 30U/L) 6. The patient has not used chemotherapy (neoadjuvant or adjuvant chemotherapy) since diagnosis 7. The investigator determines that the patient has any other condition that make her unfit to participate in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Anti-Mullerian Hormone | Before chemotherapy, within a week after last chemotherapy, 1,3,6,12,18,24 months after chemotherapy | Blood Test |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Estradiol | Before chemotherapy, within a week after last chemotherapy, 1,3,6,12,18,24 months after chemotherapy | Blood Test |
| Follicle Stimulating Hormone | Before chemotherapy, within a week after last chemotherapy, 1,3,6,12,18,24 months after chemotherapy | Blood Test |
| Menstruation | Before chemotherapy, within a week after last chemotherapy, 1,3,6,12,18,24 months after chemotherapy | Follow-up |
Outcome results
None listed